A. Roshak

发表

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

J. Jackson, A. Gilmartin, C. Imburgia, 2000, Cancer research.

Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease

A. Roshak, S. Blake, J. Callahan, 2002 .

Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures.

J. Lee, S. Kumar, A. Roshak, 2000, Osteoarthritis and cartilage.

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase.

C. Imburgia, L. Marshall, A. Roshak, 2000, Cellular signalling.

Manipulation of Distinct NFκB Proteins Alters Interleukin-1β-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation*

J. Jackson, L. Marshall, A. Roshak, 1996, The Journal of Biological Chemistry.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytosolic 85-kDa Phospholipase A2-mediated Release of Arachidonic Acid Is Critical for Proliferation of Vascular Smooth Muscle Cells*

L. Marshall, A. Roshak, M. McCord, 1997, The Journal of Biological Chemistry.

Depletion of Human Monocyte 85-kDa Phospholipase A2 Does Not Alter Leukotriene Formation*

L. Marshall, A. Roshak, B. Bolognese, 1997, The Journal of Biological Chemistry.

Respective roles of the 14 kDa and 85 kDa phospholipase A2 enzymes in human monocyte eicosanoid formation.

L. Marshall, A. Roshak, B. Bolognese, 1999, Advances in experimental medicine and biology.

Decreased nuclear factor-κB DNA binding activity following permanent focal cerebral ischaemia in the rat

J. Roberts, A. A. Parsons, A. Roshak, 2000, Neuroscience Letters.

The FASEB Journal express article 10.1096/fj.03-0170fje. Published online Novermber 3, 2003. Regulation of TNF-α and IFN-γ induced CXCL10

H. Sarau, J. Foley, A. Roshak, 2022 .

SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock.

J. Adams, L. Marshall, A. Roshak, 1995, The Journal of pharmacology and experimental therapeutics.

Characterization of phospholipase A2 from human nasal lavage.

R. Naclerio, A. Roshak, F. Chilton, 1994, American journal of respiratory cell and molecular biology.

Scytonemin-a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases

Christopher S. Stevenson, C. Stevenson, W. Gerwick, 2002, Inflammation Research.

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation*

L. Marshall, A. Roshak, E. A. Capper, 2000, The Journal of Biological Chemistry.

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis.

L. Marshall, A. Roshak, B. Bolognese, 2000, The Journal of pharmacology and experimental therapeutics.

Evidence that 85 kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes.

L. Marshall, A. Roshak, C. Sung, 1997, Biochimica et biophysica acta.

Coexistence of two biochemically distinct phospholipase A2 activities in human platelet, monocyte, and neutrophil.

L. Marshall, A. Roshak, 1993, Biochemistry and cell biology = Biochimie et biologie cellulaire.

The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore

William H Gerwick, Christopher S. Stevenson, Robert S Jacobs, 2002, Journal of Pharmacology and Experimental Therapeutics.

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

James F. Callahan, A. Roshak, B. Bolognese, 2005, Journal of Pharmacology and Experimental Therapeutics.

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

S. Heo, S. Lim, B. Cho, 2020, Cancer discovery.

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

M. Ahn, E. Cho, S. Shreeve, 2021 .

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Shreeve, K. Patel, J. Curtin, 2021 .

P15.03 A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC

A. Roshak, R. Knoblauch, T. Hida, 2021 .

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Inhibition of NFκB-Mediated Interleukin-1β-Stimulated Prostaglandin E2 Formation by the Marine Natural Product Hymenialdisine

L. Marshall, A. Roshak, M. Chabot‐Fletcher, 1997 .

Recombinant human secretory phospholipase A2: Purification and characterization of the enzyme for active site studies

M. Mclaughlin, G. P. Livi, C. F. Bennett, 1992, Journal of molecular recognition : JMR.

Anti‐human RP105 sera induces lymphocyte proliferation

L. Marshall, A. Roshak, J. Terrett, 1999, Journal of leukocyte biology.

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

A. Mansfield, S. Ou, R. Salgia, 2022, Journal of Clinical Oncology.

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

N. Girard, Dohoung Kim, B. Cho, 2021 .

Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation.

L. Marshall, A. Roshak, C. Sung, 1994, The Journal of pharmacology and experimental therapeutics.

Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis.

L. Marshall, A. Roshak, G. Sathe, 1994, The Journal of biological chemistry.

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease.

A. Roshak, S. Blake, J. Callahan, 2002, Current opinion in pharmacology.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

K. Patel, J. Curtin, A. Roshak, 2021 .

Suppression of human synovial fibroblast 85 kDa phospholipase A2 by antisense reduces interleukin-1 beta induced prostaglandin E2.

L. Marshall, A. Roshak, E. Mochan, 1996, The Journal of rheumatology.

Utility of oligonucleotides as tools to study the function and regulation of 85 kDa phospholipase A2.

L. Marshall, A. Roshak, 1998, Antisense & nucleic acid drug development.

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

R. Salgia, P. Janne, B. Cho, 2021, Journal of Thoracic Oncology.

Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation.

J. Jackson, L. Marshall, A. Roshak, 1996, The Journal of biological chemistry.

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

S. Ou, Keunchil Park, Dong-Wan Kim, 2023, Nature Medicine.

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

R. Govindan, Keunchil Park, R. Salgia, 2022, Annals of Oncology.